Company intelligence / Profile preview

OmRx Oncology

San Diego, California, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

OmRx Oncology’s lead program OX-4224 is a small molecule oral PD-1/PD-L1 checkpoint inhibitor being evaluated in a Phase 2 trial for metastatic non-small cell lung cancer (NSCLC) patients with PD-L1–positive tumors who have not received prior immune checkpoint inhibitors, primarily in India[1][2][3][5][7]. The clinical results are pending, but the program aims to demonstrate efficacy and safety in second-line monotherapy settings, with future plans for global expansion and all-oral combination regimens[1][2][5].

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

evixapodlin

Partnerships

Gilead Sciences (OX-4224 licensed from Gilead Sciences)Scripps Research (R&D support)

Beyond the preview

Go deeper on OmRx Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OmRx Oncology.

Explore the full profile